Propranolol as an adjunct therapy for hyperthyroid tremor.
We evaluated the use of propranolol as an adjunct to carbimazole in the treatment of hyperthyroid tremor and tachycardia in a double-blind, cross-over and placebo-controlled study. Seven patients were given carbimazole plus either placebo or propranolol (40 mg) for 1 month and then switched to the alternative adjunct treatment for a further month. All patients showed significant improvements (p < 0.001) of heart rate and tremor amplitude after 1 or 2 months from baseline. One month after the baseline, the mean improvements of heart rate were 23% for the carbimazole + placebo group and 38% for carbimazole + propranolol group. Tremor also improved during the 1st month of the study by 31% in the carbimazole + placebo group versus 59% in the carbimazole + propranolol group. Whereas further improvements were observed in both variables in those receiving propranolol as the second adjunct treatment, this was not the case in those who received placebo during the same period. These findings confirm that the beta-blocker propranolol is a useful adjunct in the early treatment of both the tremor and tachycardia of hyperthyroidism.
Henderson
J M
JM
Policlinique de Neurologie, CHUV, Suisse.
Portmann
L
L
Van Melle
G
G
Haller
E
E
Ghika
J A
JA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D002231:Carbimazole / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use*; D014202:Tremor / Q000209:etiology*
D000319:Adrenergic beta-Antagonists; D013956:Antithyroid Agents; D010919:Placebos; D002231:Carbimazole; D011433:Propranolol